Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Electronic Warning Systems in Diagnosis and Treatment of AKI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03119480
Recruitment Status : Completed
First Posted : April 18, 2017
Last Update Posted : October 17, 2018
Sponsor:
Information provided by (Responsible Party):
Ding Feng, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Brief Summary:

To set up electronic early warning system of AKI patients; To develop AKI's intervention, the follow-up process, and the renal physician is responsible for the implementation.

To Observe the method after implementing the treatment efficacy of AKI and the differences between the traditional treatment process.


Condition or disease Intervention/treatment
Acute Kidney Injury Device: electronic alerts

Detailed Description:

To set up electronic early warning system according to KDIGO AKI diagnosis standard, real-time monitoring of hospitalized patients with renal function data, real-time detection of AKI patients, notify the diagnosis of renal physician; To develop AKI's intervention, the follow-up process, and the renal physician is responsible for the implementation.

To Observe the method after implementing the treatment efficacy of AKI and the differences between the traditional treatment process.

Layout table for study information
Study Type : Observational
Actual Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Electronic Warning Systems in the Process of Diagnosis and Treatment of Patients With Acute Kidney Injury
Actual Study Start Date : October 15, 2017
Actual Primary Completion Date : October 15, 2018
Actual Study Completion Date : October 15, 2018

Group/Cohort Intervention/treatment
Hospital-acquired AKI
Adult patients with Hospital-acquired AKI
Device: electronic alerts
electronic alerts for AKI




Primary Outcome Measures :
  1. all-cause mortality [ Time Frame: at 7 days after alert ]
    death at 7 days after alert


Secondary Outcome Measures :
  1. dialysis [ Time Frame: at 7 days after alert ]
    dialysis at 7 days after alert

  2. change in creatinine [ Time Frame: at 7 days after alert ]
    relative maximum change in creatinine



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
adult patients aged>18 years,with hospital-acquired acute kidney injury, from a university-affiliated hospital in Shanghai, China
Criteria

Inclusion Criteria:

Eligible participants were adults aged 18 years or older who were in hospital with stage 1 or greater acute kidney injury as defined by Kidney Disease Improving Global Outcomes creatinine-based criteria.

Exclusion Criteria:

Exclusion criteria were initial hospital creatinine 4•0 mg/dL (to convert to μmol/L, multiply by 88•4) or greater, fewer than two creatinine values measured, inability to determine the covering provider, admission to hospice or the observation unit, previous randomisation, or end-stage renal disease.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03119480


Locations
Layout table for location information
China, Shanghai
Shanghai Ninth People's Hospital
Shanghai, Shanghai, China, 200011
Sponsors and Collaborators
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Investigators
Layout table for investigator information
Study Director: Feng Ding, PhD Division of Nephrology,Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University
Layout table for additonal information
Responsible Party: Ding Feng, Kidney internal medicine professor, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
ClinicalTrials.gov Identifier: NCT03119480    
Other Study ID Numbers: AKI-2017-01
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: October 17, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ding Feng, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University:
Acute Kidney Injury
Electronic alerts
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases